Bajaj Healthcare (BHL), a manufacturer of APIs, intermediates and formulations, has announced to start commercial production of Nimesulide API at Plot No N-92, MIDC, Tarapur in Maharashtra.
Nimesulide API is used for relief from pain and prevention of fever. BHL has received approval from FDA Maharashtra (India), to manufacture and market Nimesulide API as approved medication for pain relief and prevention of fever in India and will commence its commercial production from 3 September 2021 onwards.
In FY21, the company has acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises three manufacturing units and one engineering unit at MIDC, Tarapur and having installed capacity of 111 tonne per month.
BHL has received an approval to begin its commercial production in one of the manufacturing unit acquired under SARFAESI Act, 2002 at Plot No N-92, MIDC. This manufacturing unit has installed capacity of 40 tonne per month.
FDA Maharashtra (India) has granted permission to manufacture and sales in the domestic as well as in overseas market.